VICTORIA, June 26, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF),
the industry leader in the discovery of novel, therapeutic
monoclonal antibodies, announces that from this point forward it
will guarantee the success of campaigns powered by its proprietary
B cell Select™ Antibody Discovery platform.
Pioneering innovative antibody discovery, ImmunoPrecise
harnesses its species agnostic platform, driven by scientific
experts with over a decade of experience in single B cell services,
to leverage its already industry-wide, unprecedented success rates.
B cell technologies is a space where IPA has spent years
differentiating itself from competitors. The Company understands
the importance to ensure clients can readily ascertain who has the
depth of experience and proven success to partner with pharma,
without jeopardizing outcomes.
It can be to the detriment of pharmaceutical partners and
patients when therapeutic programs are continually repeated due to
low success rates, oftentimes a result of contract organizations'
lack of experience in modern technologies, which can take years to
master, or their use of outdated platforms.
"We believe that backing our expertise with a success guarantee,
in a royalty-free service offering, aligns our B Cell Select™
platform with the goals of our clients worldwide", stated IPA
President and CEO, Dr. Jennifer
Bath. "Ultimately, our optimized platform, exhibiting a
minimum 94% success rate, along with our success guarantee,
decreases turnaround time, attenuates risk, and reduces the overall
cost for our clients in getting antibody therapeutics to the
clinic. We are both humbled and honored to be servicing this
niche."
For more information about ImmunoPrecise's proprietary B cell
Select™️ platform visit
https://www.immunoprecise.com/services/b-cell-select/
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located in Victoria, British Columbia, in collaboration with its
wholly-owned subsidiary operations at ImmunoPrecise Antibodies
Europe (formerly ModiQuest Research), in Oss, and U-Protein
Express, in Utrecht, both in the Netherlands. The Company operates globally to
offer a continuum of superior antibody services, from target
analysis to pre-clinical studies.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.